Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet the following three criteria at study entry within a 24-hour period: 1) PaO2/FiO2 less than or equal to 300 (if altitude is more than 1000 meters, then PaO2/FiO2 less than or equal to 300 x \[barometric pressure/760\]), 2) bilateral infiltrates (patchy, diffuse, homogeneous, or asymmetric) consistent with pulmonary edema on frontal chest radiograph, and 3) requirement for positive pressure ventilation via endotracheal tube~* No clinical evidence of left-sided cardiac failure to account for bilateral pulmonary infiltrates~* Intention of primary medical team to enterally feed the patient~* Undergoes enteral feeding within 48 hours of meeting inclusion criteria~Exclusion Criteria:~* Neuromuscular disease that impairs ability to breath without assistance, such as cervical spinal cord injury at level C5 or higher, amyotrophic lateral sclerosis, Guillain-Barré syndrome, or myasthenia gravis~* Pregnant or breastfeeding~* Severe chronic respiratory disease. More information about this criterion can be found in the protocol.~* Burns on greater than 40% total body surface area~* Malignancy or other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%. More information about this criterion can be found in the protocol.~* Allogeneic bone marrow transplant within the 5 years before study entry~* Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)~* Severe chronic liver disease (Child-Pugh score of 11 to 15)~* Diffuse alveolar hemorrhage from vasculitis~* Morbid obesity, defined as 1 kg/cm body weight~* Unwilling or unable to use the ARDS network 6 mL/kg PBW ventilation protocol~* Moribund patient not expected to survive 24 hours~* No intent to obtain central venous access for monitoring intravascular pressures~* More than 72 hours since mechanical ventilation initiated~* Refractory shock. More information about this criterion can be found in the protocol.~* Unable to obtain enteral access~* Presence of partial or complete mechanical bowel obstruction~* Presence of ischemia or infarction~* Current total parenteral nutrition (TPN) use or intent to use TPN within 7 days of study entry~* Severe malnutrition with body mass index less than 18.5 or loss of more than 30% total body weight in the 6 months before study entry~* Laparotomy expected within 7 days of study entry~* Unable to raise head of bed 30 to 45 degrees~* Short-bowel syndrome or absence of gastrointestinal tract~* Presence of high-output (greater than 500 cc/day) enterocutaneous fistula~* International normalized ratio greater than 5.0, platelet count less than 30,000/mm3, or history of bleeding disorder~* Intracranial hemorrhage within the 1 month before study entry~* Allergy to enteral formula, omega-3 fatty acids, GLA, vitamin E, vitamin C, beta-carotene, taurine, or L-carnitine~* Requirement for, or physician insistence on, enteral formula supplemented with omega-3 fatty acids (ex: Oxepa®, Impact®) or providing omega-3 fatty acid, GLA, or antioxidant supplementation

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive initial minimal (trophic) enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
- 2 (Type: EXPERIMENTAL): Participants will receive initial full-calorie enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
- 3 (Type: EXPERIMENTAL): Participants will receive initial minimal (trophic) enteral feeding and the placebo supplement
- 4 (Type: PLACEBO_COMPARATOR): Participants will receive initial full-calorie enteral feeding and the placebo supplement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy